GlassScriptPhysician profile
Carrisa S Patrick
NPI 1225516826
$5,877.32
in general payments reported to CMS, 2019-2025
31 companies · $602 in 2025
The $602 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,295 · 2022: $1,250 · 2023: $1,630 · 2024: $1,101 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,285.28 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $943.86 | 2021-2025 | |
| Pfizer INC. | $457.35 | 2021-2025 | |
| Novo Nordisk INC | $422.92 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $413.54 | 2021-2024 | |
| Glaxosmithkline, LLC. | $339.90 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $274.69 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $200.57 | 2022 | |
| Eisai INC. | $194.54 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.82 | 2021-2025 | Caplyta |
| Amgen INC. | $136.90 | 2021-2025 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceuticals, INC. | $133.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $127.51 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $108.39 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.85 | 2022-2023 | Trulance, Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $89.34 | 2021-2024 | Contrave |
| Corium, LLC | $70.82 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $68.29 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $63.91 | 2021-2022 | |
| Abbott Laboratories | $44.26 | 2023 | Freestyle Libre |
| Lundbeck LLC | $31.02 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $30.81 | 2024 | Auvelity |
| Amarin Pharma, INC. | $29.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.44 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $23.64 | 2022 | |
| Neurocrine Biosciences, INC. | $21.66 | 2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $20.81 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.26 | 2021 | |
| Esperion Therapeutics, INC. | $14.07 | 2021 | |
| Genentech USA, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrisa Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.